Keyword Suggestion
Domain Informations
Network
- inetnum : 23.192.0.0 - 23.223.255.255
- name : AKAMAI
- handle : NET-23-192-0-0-1
- status : Direct Allocation
- created : 1999-01-21
- changed : 2023-10-24
Owner
- organization : Akamai Technologies, Inc.
- handle : AKAMAI
- address : Array,Cambridge,MA,02142,US
Abuse
- handle : NUS-ARIN
- name : NOC United States
- phone : +1-617-444-2535
- email : [email protected]
Technical support
- handle : SJS98-ARIN
- name : Schecter, Steven Jay
- phone : +1-617-274-7134
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 23.221.220.42
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Site Inspections
Port Scanner (IP: 23.221.220.42)
Spam Check (IP: 23.221.220.42)
Recent Searched Sites
› Aniwave-v1.s3.amazonaws.com (3 seconds ago) / US
› Petshop2gocr.com (1 seconds ago) / US
› Khadak.com (19 seconds ago) / US
› Home.alibabagroup.com (2 seconds ago) / US
› Peomaryland.org (2 seconds ago) / US
› Thervss.com (3 seconds ago) / US
› Hillspet.pl (3 seconds ago) / US
› Atlasinfonet.ucoz.com (5 seconds ago) / GB
› Brandoo.pl (14 seconds ago) / PL
› Solidiut.com (2 seconds ago) / US
› Repositorio.aemet.es (1 seconds ago) / ES
› Email.whois.co.kr (6 seconds ago) / KR
› Rivfast.com (7 seconds ago) / US
› Breakingtheonepercent.com (7 seconds ago) / US
› Images.51microshop.com (9 seconds ago) / US
› Guions.cat (17 seconds ago) / US
› Wuwqn.wiki (1 seconds ago) / US
› Mk.insterne.com (18 seconds ago) / US
› Actionmarineinc.com (10 seconds ago) / US
› Farazteam.com (2 seconds ago) / IR
Websites Listing
We found Websites Listing below when search with investors.coherus.com on Search Engine
Contact Us | Coherus BioSciences, Inc.
Email Alerts; Contact Us Transfer Agent. EQ Shareowner Services P.O. Box 64874 St. Paul, MN 55164-0856 - Or - EQ Shareowner Services 1110 Centre Point Curve, Suite 101 Mendota Heights, MN 55120-4100 Phone: (800) 468-9716 or (651) 450-4064 (outside the U.S.) Web Address: www.shareowneronline.com. Contact Us. To request information, please fill out and …
Investors.coherus.comCoherus Names Paul Reider Chief Commercial Officer ...
2022-02-15 · About Coherus BioSciences Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its portfolio of FDA-approved products. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for ...
Investors.coherus.comContact Us | Coherus BioSciences
Address: 333 Twin Dolphin Drive, Suite 600. Redwood City, CA 94065
Coherus.comChoice Without Compromise - Coherus BioSciences
Coherus BioSciences, Inc. is proud to team up with our UDENYCA ® (pegfilgrastim-cbqv) biomanufacturing partner KBI Biopharma and their parent company JSR Life Sciences to donate $40,000 to the Boulder County Wildfire Fund to support the heroic first responders who helped save the community from the recent Marshall Fire.
Coherus.comCoherus BioSciences Inc. (CHRS): A Brand-New Prospect for ...
2022-03-22 · For the readers interested in the stock health of Coherus BioSciences Inc. (CHRS). It is currently valued at $12.16. When the transactions were called off in the previous session, Stock hit the highs of $13.31, after setting-off with the price of $13.22. Company’s stock value dipped to $12.11 duri
Investchronicle.comOverview | Coherus BioSciences, Inc.
2022-02-15 · In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States …
Coherusbioscience.gcs-web.comCoherus Biosciences's Email Format - coherus.com Email ...
Whether you’re looking to discover the company email format for Coherus Biosciences, or specific emails for specific Coherus Biosciences employees, we’ve got you covered. Anymail finder. Coherus Biosciences coherus.com. Coherus Biosciences is based in Redwood City, California, United States Coherus Biosciences has around 300 employees Founded in 2010. …
Anymailfinder.comCoherus BioSciences Reports Fourth Quarter and Full Year ...
2022-02-17 · Net revenue, consisting of net sales of UDENYCA, was $73.4 million for the fourth quarter of 2021 compared to $110.4 million for the same period in 2020. Net revenue for 2021 was $326.6 million ...
Marketwatch.comCoherus Management to Present at Upcoming Investor ...
2022-03-04 · 42 nd Annual Cowen Health Care Conference on Wednesday, March 9 at 10:30 a.m. ET. Barclays Global Healthcare Conference on Tuesday, March 15 at 2:35 p.m. ET. Audio webcasts of these presentations ...
Marketwatch.comCoherus BioSciences (NYSE:CHRS) - Recap: Coherus ...
2022-02-17 · Coherus BioSciences beat estimated earnings by 9.8%, reporting an EPS of $-0.46 versus an estimate of $-0.51. Revenue was up $37.05 million from the same period last year. Last quarter the company ...
Benzinga.comCoherus BioSciences Inc. (CHRS): Are the Stars Lining Up ...
2022-01-14 · Coherus BioSciences Inc. (CHRS) is priced at $13.85 after the most recent trading session. At the very opening of the session, the stock price was $14.25 and reached a high price of $14.275, prior to closing the session it reached the value of $14.16. The stock touched a low price of $13.76.Recently
Investchronicle.comCoherus BioSciences Inc. (CHRS): This Stock is set to Soar ...
2022-02-23 · Let’s start up with the current stock price of Coherus BioSciences Inc. (CHRS), which is $11.12 to be very precise. The Stock rose vividly during the last session to $12.19 after opening rate of $12.16 while the lowest price it went was recorded $10.95 before closing at $12.32.Recently in News on February 17, 2022, Coherus BioSciences Reports Fourth …
Investchronicle.comCoherus BioSciences to Report Fourth ... - stockwatch.com
2022-02-11 · Starting at 5 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. After releasing fourth quarter and full year 2021 financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call Information
Stockwatch.comCoherus BioSciences (CHRS) Q4 2021 Earnings Call Transcript
2022-02-17 · For the fourth quarter and full year 2021, we reported net losses of $46 million and $287 million, respectively, on a GAAP basis. Cash used in …
Msn.comCoherus BioSciences to Report Fourth Quarter and Full Year ...
2022-02-11 · After releasing fourth quarter and full year 2021 financial results, the Company will post them on the Coherus website at https://investors.coherus.com. Conference Call Information When: Thursday ...
Finance.yahoo.comJunshi Biosciences and Coherus Expand Immuno-Oncology ...
2022-01-10 · About Coherus BioSciences Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the …
Financialpost.comCoherus and Junshi Biosciences Expand Immuno-Oncology ...
2022-01-11 · Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. A biologics license application for toripalimab for the treatment of metastatic or recurrent …
Investorvillage.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| ojaioil.com | domains.google.com | -2 Years, -285 Days |
| duicare.org | whois.godaddy.com | -2 Years, -97 Days |
| navigateacademy.net | networksolutions.com | -2 Years, -312 Days |
| braeswoodchurch.org | networksolutions.com | -1 Years, -335 Days |
| proky.io | regtons.com | -3 Years, -30 Days |
| youreverydayentertainment.com | godaddy.com | -3 Years, -181 Days |
| hafuktxt.com | namesilo.com | -2 Years, -133 Days |
| ostnimeku.com | webnic.cc | -3 Years, -4 Days |
| camptlc.com | publicdomainregistry.com | -1 Years, -196 Days |
| pacelineproducts.com | tucows.com | 4 Years, 85 Days |